ALKS vs LBRX
ALKS: Alkermes is a neuroscience-focused biopharmaceutical company developing and commercializing therapeutic treatments for complex neurological and psychiatric disorders. LBRX: A biopharmaceutical company developing LB-102, a novel, late-stage benzamide antipsychotic candidate targeting schizophrenia and mood disorders.
Side-by-side fundamentals
| Metric | ALKS | LBRX | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $43.48 | $39.23 | |
| Market cap | $7.3B | $1.3B | |
| P/E as of 2026-10-21 | 114.42 | n/a | |
| Net margin FY2025, SEC XBRL | +16.4% | n/a | |
| Operating margin FY2025, SEC XBRL | +17.2% | n/a | |
| ROE FY2025, SEC XBRL | +13.3% | -8.4% | ALKS higher |
| ROA FY2025, SEC XBRL | +9.7% | -8.1% | ALKS higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.83 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | -5.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +9.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.68 | 0.56 | |
| 1-year return as of 2026-10-21 close | +38.3% | +145.2% | LBRX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.